The tweet was deleted by the author.
But we saved everything 🙂.
Ocugen, Inc. reported several major milestones during its latest earnings call, with CEO Dr. Shankar Musunuri announcing a 130 million dollar financing deal for the second quarter of 2026.
The company also disclosed a binding term sheet to license its OCU400 therapy in the MENA region, advancement of OCU410 to Phase 3 clinical trials with RMAT designation, and ongoing commercial readiness efforts. These strategic moves underline Ocugen, Inc.’s commitment to expanding its portfolio and geographic reach ahead of key regulatory and commercialization decisions.
View post on X Loading...
Earlier, Ocugen detailed the experience of a participant in the OCU400 clinical trial for retinitis pigmentosa. The company has also reported on new gene delivery strategies for brain-targeted therapies in CNS disorders. These initiatives reflect an ongoing focus on advancing gene therapy research across multiple indications.